ABSTRACT
BACKGROUND: Activation of neurohormonal systems contributes to the progression of heart failure (HF). The mechanism(s) whereby these systems become activated is(are) not fully explained. We determined whether vagal cardiopulmonary baroreflex control of renal sympathetic nerve activity is abnormal in dogs with left ventricular (LV) dysfunction in the absence of clinical HF, and the relationship of abnormalities in baroreflexes to the development of the neurohumoral excitatory state. METHODS: LV end-systolic and end-diastolic dimensions (echocardiography), arterial baroreflex sensitivity (slope of ΔRR/Δsystolic BP during phenylephrine or nitroglycerin bolus), and neurohumoral profiles (plasma norepinephrine, renin activity, and arginine vasopressin) were measured serially in conscious dogs (n=24) with progressive LV dysfunction due to rapid ventricular pacing. LV dimensions were used to define groups with mild, moderate, and marked LV dilatation (LVD; increase in LV end-diastolic volume <15%, 15-30%, and >30% of control, respectively). Changes in renal nerve activity (RNA) were recorded in response to increases in pulmonary capillary wedge pressure (PCWP) induced by volume infusion in anesthetized, sinoaortic-denervated dogs. RESULTS: Cardiopulmonary baroreflex sensitivity (slope of %ΔRNA/ΔPCWP) for mild LVD (-17.8%/mmHg) was the same as controls (-17.7%/mmHg). However, the slopes of moderate (-5.8%/mmHg) and severe LVD (-1.9%/mmHg) were decreased significantly compared with controls (P < .05). Arterial baroreflex sensitivity was preserved at all stages of LVD. Plasma norepinephrine, renin activity, and arginine vasopressin remained unchanged after 4, 7, and 11 days of pacing. CONCLUSIONS: Vagal cardiopulmonary baroreflex control of renal sympathetic nerve activity is blunted early in the development of LVD. These abnormalities precede neurohumoral excitation and abnormal arterial baroreflexes and become apparent when LV end-diastolic volume starts to increase.
Subject(s)
Baroreflex/physiology , Heart Failure , Kidney/innervation , Parasympathetic Nervous System/physiopathology , Sympathetic Nervous System/physiopathology , Animals , Blood Pressure/physiology , Disease Models, Animal , Disease Progression , Dogs , Heart Failure/metabolism , Heart Failure/physiopathology , Heart Rate/physiology , Mechanoreceptors/physiology , Synaptic Transmission/physiologyABSTRACT
BACKGROUND: Recommendations differ regarding how blood pressure targets should vary with age. Crucial to this controversy is whether treatment benefit varies with age. METHODS: Systematic searches were conducted for trials randomizing treatment in intensive arms to the recommended SBP targets: 120-140âmmHg. Head-to-head meta-analyses and meta-regression were conducted. RESULTS: Sixteen trials met criteria. Relative to higher targets, lower targets reduced cardiovascular events, but treatment benefit differed significantly among trials due to patient age. Treatment significantly benefited older patients (mean age 77, SDâ=â72-81), relative risk (RR)â=â0.77 (0.61,0.97), Pâ=â0.025, but not younger patients (mean age 61, SDâ=â53-70), RRâ=â0.90 (0.78,1.03), Pâ=â0.121, even though the latter had much greater statistical power. The (RR in 80 year olds)/(RR in 55 year olds)â=â0.68 (0.47,0.97), Pâ=â0.036. Though statistically nonsignificant, corresponding trends for more specific outcomes favored older patients: Coronary artery disease 0.80, stroke 0.85, heart failure 0.54, and total mortality 0.76. For adverse effects this trend was 0.86 (0.33,2.26). The number needed to treat to lower targets to prevent one cardiovascular event over 10 years in eight populations declined with age by 94%+. CONCLUSION: In these novel results, for both RR and absolute risk, treating to SBPs of 120-140âmmHg versus higher targets benefited older patients more than younger patients without an age-related increase in the RR for adverse effects. Nonetheless, because all clinical trials excluded the most frail older patients, clinicians must consider individual patient characteristics such as frailty, autonomy, and cognitive ability when choosing blood pressure targets.
Subject(s)
Antihypertensive Agents , Blood Pressure/drug effects , Hypertension/drug therapy , Aged , Aged, 80 and over , Antihypertensive Agents/adverse effects , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Humans , Middle Aged , Randomized Controlled Trials as Topic , Treatment OutcomeABSTRACT
Left ventricular hypertrophy develops in 36%-41% of hypertensive patients and independently predicts cardiovascular events and total mortality. Moreover, drug-induced reduction in left ventricular mass (LVM) correlates with improved prognosis. The optimal thiazide-type diuretic for reducing LVM is unknown. Evidence regarding potency, cardiovascular events, sodium, and potassium suggested the hypothesis that "CHIP" diuretics (CHlorthalidone, Indapamide, and Potassium-sparing diuretic/hydrochlorothiazide [PSD/HCTZ]) would reduce LVM more than HCTZ. Systematic searches of five databases were conducted. Among the 38 randomized trials, a 1% reduction in systolic blood pressure (SBP) predicted a 1% reduction in LVM, P = 0.00001. CHIP-HCTZ differences in reducing LVM differed across trials (ie, heterogeneity), making interpretation uncertain. However, among the 28 double-blind trials, heterogeneity was undetectable, and HCTZ reduced LVM (percent reduction [95% CI]) by -7.3 (-10.4, -4.2), P < 0.0001. CHIP diuretics surpassed HCTZ in reducing LVM: chlorthalidone -8.2 (-14.7, -1.6), P = 0.015; indapamide -7.5 (-12.7, -2.3), P = 0.005; and all CHIP diuretics combined -7.7 (-12.2, -3.1), P < 0.001. The comparison of PSD/HCTZ with HCTZ had low statistical power but favored PSD/HCTZ: -6.0 (-14.1, +2.1), P = 0.149. Thus, compared to HCTZ, CHIP diuretics had twice the effect on LVM. CHIP diuretics did not surpass HCTZ in reducing systolic or diastolic blood pressure: -0.3 (-5.0, +4.3) and -1.6 (-5.6, +2.4), respectively. The strength of evidence that CHIP diuretics surpass HCTZ for reducing LVM was high (GRADE criteria). In conclusion, these novel results have demonstrated that CHIP diuretics reduce LVM 2-fold more than HCTZ among hypertensive patients. Although generally related to LVM, blood pressure fails to explain the superiority of CHIP diuretics for reducing LVM.
Subject(s)
Chlorthalidone/pharmacology , Diuretics, Potassium Sparing/pharmacology , Hydrochlorothiazide/pharmacology , Hypertension/drug therapy , Hypertrophy, Left Ventricular/drug therapy , Indapamide/pharmacology , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Chlorthalidone/administration & dosage , Chlorthalidone/therapeutic use , Diuretics, Potassium Sparing/administration & dosage , Diuretics, Potassium Sparing/therapeutic use , Drug Therapy, Combination/methods , Female , Humans , Hydrochlorothiazide/administration & dosage , Hydrochlorothiazide/therapeutic use , Hypertension/complications , Hypertension/physiopathology , Hypertrophy, Left Ventricular/epidemiology , Hypertrophy, Left Ventricular/physiopathology , Hypertrophy, Left Ventricular/prevention & control , Indapamide/administration & dosage , Indapamide/therapeutic use , Male , Middle Aged , Randomized Controlled Trials as Topic , Sodium Chloride Symporter Inhibitors/pharmacology , Thiazides/pharmacology , Thiazides/therapeutic useABSTRACT
Parenteral diuretics form the cornerstone of decongestion in heart failure. However, parenteral therapy routinely requires emergency room or inpatient care. A novel buffered furosemide formulation with neutral pH was developed to offer "hospital-strength" diuresis for outpatient use, including self-administration at home. Subcutaneous infusion using a biphasic delivery profile resulted in complete bioavailability (99.65%) and equivalent diuresis when compared with intravenous administration. Subcutaneous administration of buffered furosemide was well tolerated with no evidence of any drug-induced skin reactions. Subcutaneous infusion of buffered furosemide in the outpatient setting or home may help to reduce the burden of heart failure.
Subject(s)
Antihypertensive Agents/therapeutic use , Aortic Valve Insufficiency/surgery , Blood Pressure/physiology , Coronary Artery Bypass , Heart Valve Prosthesis Implantation , Hypertension/etiology , Mitral Valve Insufficiency/surgery , Aged , Aortic Valve/surgery , Aortic Valve Insufficiency/complications , Heart Rate/physiology , Humans , Hypertension/drug therapy , Hypertension/physiopathology , Male , Mitral Valve/surgery , Mitral Valve Insufficiency/complications , Postoperative Period , Ventricular Function, Left/physiologyABSTRACT
BACKGROUND: Found in 36-41% of hypertension, elevated left ventricular mass (LVM) independently predicts cardiovascular events and total mortality. Conversely, drug-induced regression of LVM predicts improved outcomes. Previous studies have favored renin-angiotensin system inhibitors (RASIs) over other antihypertensives for reducing LVM but ignored differences among thiazide-type diuretics. From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM. METHOD AND RESULTS: Systematic review yielded 12 relevant double-blind randomized trials. CHIPs were more closely associated with reduced LVM than HCTZ (Pâ=â0.004), indicating that RASIs must be compared with each diuretic separately. Publication bias favoring RASIs was corrected by cumulative analysis. For reducing LVM, HCTZ tended to be less effective than RASIs. However, the following surpassed RASIs: chlorthalidone Hedge's G: -0.37 (95% CI -0.72 to -0.02), Pâ=â0.036; indapamide -0.20 (-0.39 to -0.01), Pâ=â0.035; all CHIPs combined (with 61% of patients in one trial) -0.25 (-0.41to -0.09), Pâ=â0.002. Statistical significance (Pâ<â0.05) did not depend on any one trial. CHIPs reduction in LVM was 37% greater than that from RASIs. CHIPs superiority tended to increase with trial duration, from a negligible effect at 0.5 year to a maximal effect at 0.9-1.0 years: -0.26 (-0.43 to -0.09), Pâ=â0.003. Fifty-eight percent of patients had information on echocardiographic components of LVM: relative to RASIs, CHIPs significantly reduced end-diastolic LV internal dimension (EDLVID): -0.18 (-0.36 to -0.00), Pâ=â0.046. Strength of evidence favoring CHIPs over RASIs was at least moderate. CONCLUSION: In these novel results in patients with hypertension, CHIPs surpassed RASIs for reducing LVM and EDLVID.
Subject(s)
Diuretics/therapeutic use , Hydrochlorothiazide/therapeutic use , Hypertrophy, Left Ventricular/drug therapy , Renin-Angiotensin System/drug effects , Aged , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Chlorthalidone/therapeutic use , Diuretics, Potassium Sparing/therapeutic use , Double-Blind Method , Electrolytes , Female , Humans , Hypertension/physiopathology , Indapamide/therapeutic use , Male , Middle Aged , Randomized Controlled Trials as Topic , Regression Analysis , Sodium Chloride Symporter Inhibitors/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). OBJECTIVE/METHODS: We compared FDCs of AZL-M/CTD 20/12.5âmg once daily titrated to 40/25âmg if needed or AZL-M/CTD 40/12.5âmg once daily titrated to 80/25âmg if needed with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5âmg FDC once daily titrated to 40/25âmg if needed in a randomized, double-blind, 8-week study of 1085 participants with clinic SBP 160-190âmmHg and DBP 119âmmHg or less. Titration to higher doses occurred at week 4 if BP was at least 140/90âmmHg (≥130/80âmmHg if diabetes or chronic kidney disease). The primary endpoint was change from baseline in clinic SBP; 24-h ambulatory BP monitoring was also measured. RESULTS: Greater reductions in clinic SBP from a baseline of 165âmmHg were observed (Pâ<â0.001) in both AZL-M/CTD arms (-37.6 and -38.2âmmHg) versus OLM/HCTZ (-31.5âmmHg), despite greater dose titration in the OLM/HCTZ group. At 8 weeks, both AZL-M/CTD FDCs reduced 24-h SBP more than OLM/HCTZ (-26.4 and -27.9 versus -20.7âmmHg; both Pâ<â0.001), and higher proportions in both AZL-M/CTD groups achieved target BP compared with the OLM/HCTZ group (69.4 and 68.9 versus 54.7%, both Pâ<â0.001). Adverse events leading to drug discontinuation occurred in 6.2, 9.5, and 3.1% with the AZL-M/CTD lower and higher doses, and OLM/HCTZ, respectively. CONCLUSION: This large, titration-to-target BP study demonstrated AZL-M/CTD FDCs to have superior antihypertensive efficacy compared with the maximum approved dose of OLM/HCTZ.
Subject(s)
Antihypertensive Agents/administration & dosage , Benzimidazoles/administration & dosage , Chlorthalidone/administration & dosage , Diuretics/administration & dosage , Hydrochlorothiazide/administration & dosage , Hypertension/drug therapy , Imidazoles/administration & dosage , Oxadiazoles/administration & dosage , Tetrazoles/administration & dosage , Aged , Blood Pressure/drug effects , Double-Blind Method , Drug Combinations , Female , Humans , Hypertension/physiopathology , Male , Middle AgedABSTRACT
Diuretics are the most commonly prescribed class of drugs in patients with heart failure, and in the short term they remain the most effective treatment for relief from fluid congestion. This article reviews the mode of action of the various diuretic classes and the physiologic adaptations that follow and sets up the basis for their use in the treatment of volume-retaining states, particularly as applies to the elderly. In addition, the article reviews the common side effects related to diuretics.
Subject(s)
Diuretics/therapeutic use , Heart Failure/drug therapy , Age Factors , Aged , HumansABSTRACT
The efficacy and safety of azilsartan medoxomil (AZL-M) were evaluated in African-American patients with hypertension in a 6-week, double-blind, randomized, placebo-controlled trial, for which the primary end point was change from baseline in 24-hour mean systolic blood pressure (BP). There were 413 patients, with a mean age of 52 years, 57% women, and baseline 24-hour BP of 146/91 mm Hg. Treatment differences in 24-hour systolic BP between AZL-M 40 mg and placebo (-5.0 mm Hg; 95% confidence interval, -8.0 to -2.0) and AZL-M 80 mg and placebo (-7.8 mm Hg; 95% confidence interval, -10.7 to -4.9) were significant (P≤.001 vs placebo for both comparisons). Changes in the clinic BPs were similar to the ambulatory BP results. Incidence rates of adverse events were comparable among the treatment groups, including those of a serious nature. In African-American patients with hypertension, AZL-M significantly reduced ambulatory and clinic BPs in a dose-dependent manner and was well tolerated.
Subject(s)
Angiotensin Receptor Antagonists/pharmacology , Blood Pressure Monitoring, Ambulatory/methods , Blood Pressure/drug effects , Hypertension/drug therapy , Adult , Black or African American , Angiotensin Receptor Antagonists/administration & dosage , Angiotensin Receptor Antagonists/adverse effects , Antihypertensive Agents/therapeutic use , Benzimidazoles/administration & dosage , Benzimidazoles/adverse effects , Benzimidazoles/pharmacology , Blood Pressure Monitoring, Ambulatory/statistics & numerical data , Double-Blind Method , Female , Humans , Hypertension/classification , Hypertension/ethnology , Male , Middle Aged , Oxadiazoles/administration & dosage , Oxadiazoles/adverse effects , Oxadiazoles/pharmacology , Treatment Outcome , United States/ethnologyABSTRACT
OBJECTIVE: This double-blind, placebo-controlled, interventional trial was conducted to investigate the effects of rotigotine patch on periodic limb movement (PLM)-associated nocturnal systolic blood pressure (SBP) elevations. METHODS: Patients with moderate to severe restless legs syndrome (RLS) were randomized to rotigotine (optimal dose [1-3 mg/24 h]) or placebo. Continuous beat-to-beat blood pressure (BP) assessments were performed during polysomnography at baseline and at the end of 4-week maintenance. Primary outcome was change in number of PLM-associated SBP elevations (defined as slope of linear regression ≥2.5 mm Hg/beat-to-beat interval over 5 consecutive heartbeats [≥10 mm Hg]). Additional outcomes were total SBP elevations, PLM-associated and total diastolic BP (DBP) elevations, periodic limb movements index (PLMI), and PLM in sleep arousal index (PLMSAI). RESULTS: Of 81 randomized patients, 66 (37 rotigotine, 29 placebo) were included in efficacy assessments. PLM-associated SBP elevations were significantly reduced with rotigotine vs placebo (least squares mean treatment difference [95% confidence interval (CI)] -160.34 [-213.23 to -107.45]; p < 0.0001). Rotigotine-treated patients also had greater reduction vs placebo in total SBP elevations (-161.13 [-264.47 to -57.79]; p = 0.0028), PLM-associated elevations (-88.45 [-126.12 to -50.78]; p < 0.0001), and total DBP elevations (-93.81 [-168.45 to -19.16]; p = 0.0146), PLMI (-32.77 [-44.73 to -20.80]; p < 0.0001), and PLMSAI (-7.10 [-11.93 to -2.26]; p = 0.0047). Adverse events included nausea (rotigotine 23%; placebo 8%), headache (18% each), nasopharyngitis (18%; 8%), and fatigue (13%; 15%). CONCLUSIONS: Further investigation is required to determine whether reductions in nocturnal BP elevations observed with rotigotine might modify cardiovascular risk. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with moderate to severe RLS, rotigotine at optimal dose (1-3 mg/24 h) reduced PLM-associated nocturnal SBP elevations.
Subject(s)
Blood Pressure/drug effects , Dopamine Agonists/administration & dosage , Nocturnal Myoclonus Syndrome/drug therapy , Restless Legs Syndrome/physiopathology , Tetrahydronaphthalenes/administration & dosage , Thiophenes/administration & dosage , Adolescent , Adult , Aged , Blood Pressure/physiology , Blood Pressure Determination , Dopamine Agonists/adverse effects , Double-Blind Method , Heart Rate/drug effects , Humans , Least-Squares Analysis , Middle Aged , Nocturnal Myoclonus Syndrome/complications , Nocturnal Myoclonus Syndrome/physiopathology , Photoperiod , Polysomnography , Restless Legs Syndrome/complications , Restless Legs Syndrome/drug therapy , Severity of Illness Index , Tetrahydronaphthalenes/adverse effects , Thiophenes/adverse effects , Transdermal Patch/adverse effects , Treatment Outcome , Young AdultABSTRACT
This review and update focuses on the clinical features of hydrochlorothiazide (HCTZ), the thiazide-like agents chlorthalidone (CTDN) and indapamide (INDAP), potassium-sparing ENaC inhibitors and aldosterone receptor antagonists, and loop diuretics. Diuretics are the second most commonly prescribed class of antihypertensive medication, and thiazide-related diuretics have increased at a rate greater than that of antihypertensive medications as a whole. The latest hypertension guidelines have underscored the importance of diuretics for all patients, but particularly for those with salt-sensitive and resistant hypertension. HCTZ is 4.2-6.2 systolic mm Hg less potent than CTDN, angiotensin-converting enzyme inhibitors, beta blockers, and calcium channel blockers by 24-hour measurements and 5.1mm Hg systolic less potent than INDAP by office measurements. For reducing cardiovascular events (CVEs), HCTZ is less effective than enalapril and amlodipine in randomized trials, and, in network analysis of trials, it is less effective than CTDN and HCTZ-amiloride. Combined with thiazide-type diuretics, potassium-sparing agents decrease ventricular ectopy and reduce the risk for sudden cardiac death relative to thiazide-type diuretics used alone. A recent synthesis of 44 trials has shown that the relative potencies in milligrams among spironolactone (SPIR), amiloride, and eplerenone (EPLER) are approximately from 25 to 10 to 100, respectively, which may be important when SPIR is poorly tolerated. SPIR reduces proteinuria beyond that provided by other renin angiotensin aldosterone inhibitors. EPLER also reduces proteinuria and has beneficial effects on endothelial function. While guidelines often do not differentiate among specific diuretics, this review demonstrates that these distinctions are important for managing hypertension.
Subject(s)
Diuretics/therapeutic use , Hypertension/drug therapy , HumansABSTRACT
BACKGROUND: Potassium-sparing diuretics (PSDs) are valuable antihypertensives with additional benefits unrelated to control of systolic blood pressure (SBP). However, their key parameters affecting SBP and serum potassium are poorly defined, fostering underutilization. METHOD: Consequently, we conducted systematic reviews and meta-analyses, yielding 3668 articles and ultimately 84 randomized comparisons. RESULTS: For office SBP, overall placebo-adjusted changes were triamterene -1.9 (low dose only), amiloride -9.9, spironolactone -13.2, and eplerenone -9.2. Differences in antihypertensive effect were due to potency rather than efficacy. Doubling amiloride, eplerenone, and spironolactone doses reduced SBP (95% confidence limits) on average by -2.3 (-3.1, -1.5). Relative antihypertensive potencies were spironolactone>amiloride>eplerenone. Spironolactone had significantly greater antihypertensive potency than amiloride, -4.0 (-7.4, -0.6), and eplerenone, -5.5 (-7.4, -3.6). Dose equivalencies were eplerenone-spironolactone 4.5-to-1 (e.g., eplerenone 125â¼spironolactone 25), amiloride-spironolactone 3.3-to-1, and eplerenone-amiloride 1.4-to-1. Increases in serum potassium from amiloride and spironolactone at commonly used doses averaged 0.14-0.29âmEq/l; the dose doubling effect was 0.16 (0.10, 0.22). Spironolactone caused greater hyperkalemia than amiloride across their dose ranges: 0.14, Pâ=â0.043. Seven features make important bias unlikely: a comprehensive literature search, adjustment for covariates, all models explaining 95-100% of the between-study variability, similar dose doubling effects among PSDs, two different methods giving the same potency sequence, similar results from double blind comparisons, and similar results for eplerenone versus spironolactone from analysing direct comparison data (i.e., no meta-regression) for office and 24-h SBP. CONCLUSION: This synthesis accomplishes for PSDs what has already been achieved for thiazide-type diuretics and other antihypertensives and can guide the application of these underutilized medicines.
Subject(s)
Antihypertensive Agents/administration & dosage , Blood Pressure/drug effects , Potassium/blood , Amiloride/administration & dosage , Antihypertensive Agents/pharmacokinetics , Antihypertensive Agents/therapeutic use , Dose-Response Relationship, Drug , Eplerenone , Humans , Hyperkalemia/chemically induced , Sodium Chloride Symporter Inhibitors/pharmacokinetics , Sodium Chloride Symporter Inhibitors/therapeutic use , Spironolactone/administration & dosage , Spironolactone/analogs & derivatives , Spironolactone/pharmacokinetics , Therapeutic Equivalency , Triamterene/administration & dosage , Triamterene/pharmacokineticsSubject(s)
Advisory Committees/standards , American Heart Association , Athletes , Cardiology/standards , Cardiovascular Abnormalities/diagnosis , Hypertension/diagnosis , Blood Pressure/physiology , Cardiology/methods , Cardiovascular Abnormalities/epidemiology , Exercise/physiology , Humans , Hypertension/epidemiology , Practice Guidelines as Topic/standards , United States/epidemiologyABSTRACT
A high fat meal, frequently known as western diet (WD), exacerbates atherosclerosis and diabetes. Both these diseases are frequently associated with renal failure. Recent studies have shown that lipopolysaccharide (LPS) leaks into the circulation from the intestine in the setting of renal failure and after WD. However, it is not clear how renal function and associated disorders are affected by LPS. This study demonstrates that circulatory LPS exacerbates renal insufficiency, atherosclerosis and glucose intolerance. Renal insufficiency was induced by 2/3 nephrectomy in LDL receptor knockout mice. Nx animals were given normal diet (Nx) or WD (Nx+WD). The controls were sham operated animals on normal diet (control) and WD (WD). To verify if LPS plays a role in exaggerating renal insufficiency, polymyxin (PM), a known LPS antagonist, and curcumin (CU), a compound known to ameliorate chronic kidney disease (CKD), was given to Nx animals on western diet (Nx+WD+PM and Nx+WD+CU, respectively). Compared to control, all other groups displayed increased circulatory LPS. The Nx+WD cohort had the highest levels of LPS. Nx group had significant renal insufficiency and glucose intolerance but not atherosclerosis. WD had intense atherosclerosis and glucose intolerance but it did not show signs of renal insufficiency. Compared to other groups, Nx+WD had significantly higher cytokine expression, macrophage infiltration in the kidney, renal insufficiency, glucose intolerance and atherosclerosis. PM treatment blunted the expression of cytokines, deterioration of renal function and associated disorders, albeit not to the levels of Nx, and was significantly inferior to CU. PM is a non-absorbable antibiotic with LPS binding properties, hence its beneficial effect can only be due to its effect within the GI tract. We conclude that LPS may not cause renal insufficiency but can exaggerate kidney failure and associated disorders following renal insufficiency.
Subject(s)
Atherosclerosis/etiology , Diet, High-Fat/adverse effects , Diet, Western/adverse effects , Glucose Intolerance/etiology , Hyperglycemia/etiology , Lipopolysaccharides/metabolism , Renal Insufficiency/etiology , Animals , Atherosclerosis/drug therapy , Atherosclerosis/metabolism , Atherosclerosis/pathology , Cholesterol/adverse effects , Curcumin/pharmacology , Dietary Fats/adverse effects , Disease Models, Animal , Gene Expression , Glucose Intolerance/drug therapy , Glucose Intolerance/metabolism , Glucose Intolerance/pathology , Hyperglycemia/drug therapy , Hyperglycemia/metabolism , Hyperglycemia/pathology , Intestinal Mucosa/metabolism , Intestines/drug effects , Intestines/pathology , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Macrophages/drug effects , Macrophages/metabolism , Macrophages/pathology , Mice , Mice, Knockout , Nephrectomy/adverse effects , Polymyxins/pharmacology , Receptors, LDL/deficiency , Receptors, LDL/genetics , Renal Insufficiency/metabolism , Renal Insufficiency/pathology , Renal Insufficiency/prevention & controlSubject(s)
Advisory Committees , American Heart Association , Athletes , Cardiology/standards , Cardiovascular Abnormalities/therapy , Hypertension/prevention & control , Adolescent , Adult , Cardiovascular Abnormalities/diagnosis , Cardiovascular Abnormalities/epidemiology , Child , Female , Humans , Hypertension/diagnosis , Hypertension/epidemiology , Male , Practice Guidelines as Topic/standards , Risk Reduction Behavior , United States/epidemiology , Young AdultABSTRACT
This scientific statement provides a summary of presentations and discussions at a cardiovascular Think Tank co-sponsored by the American Society of Hypertension (ASH), the United States Food and Drug Administration (FDA), and the National Heart, Lung, and Blood Institute (NHLBI) held in North Bethesda, Maryland, on June 26, 2014. Studies of device therapies for the treatment of hypertension are requested by regulators to evaluate their safety and efficacy during their development programs. Think Tank participants thought that important considerations in undertaking such studies were: (1) Preclinical assessment: how likely it is that both efficacy and safety data indicating benefit in humans will be obtained, and/or whether a plausible mechanism of action for efficacy can be identified; (2) Early human trial(s): the ability to determine that the device has an acceptable benefit-to-risk balance for its use in the intended patient population and without the influence of drug therapy during a short-term follow-up period; and (3) Pivotal Phase III trial(s): the ability to prove the effectiveness of the device in a broad population in which the trial can be made as non-confounded as possible while still allowing for the determination for benefits when added to antihypertensive therapies.
Subject(s)
Denervation/methods , Hypertension/surgery , Kidney/innervation , Animals , Antihypertensive Agents/therapeutic use , Biomarkers/analysis , Clinical Trials as Topic , Humans , Hypertension/drug therapy , Hypertension/physiopathologyABSTRACT
Hydrochlorothiazide (HCTZ) has often been contrasted with chlorthalidone, but relatively little is known about HCTZ versus indapamide (INDAP). This systematic review retrieved 9765 publications, and from these, it identified 14 randomized trials with 883 patients comparing HCTZ with INDAP and chlorthalidone on antihypertensive potency or metabolic effects. To make fair comparisons, the dose of the diuretic in each arm was assigned 1 of 3 dose levels. In random effects meta-analysis, INDAP and chlorthalidone lowered systolic blood pressure more than HCTZ: -5.1 mm Hg (95% confidence interval, -8.7 to -1.6); P=0.004 and -3.6 mm Hg (95% confidence interval, -7.3 to 0.0); P=0.052, respectively. For both comparisons, there was minimal heterogeneity in effect across trials and no evidence for publication bias. The HCTZ-INDAP contrast was biased in favor of greater HCTZ potency because of a much greater contribution to the overall effect from trials in which the HCTZ arm had a higher dose level than the INDAP arm. For the HCTZ-INDAP comparison, no single trial was responsible for the overall result nor was it possible to detect significant modifications of this comparison by duration of follow-up, high- versus low-bias trials, or the presence or absence of background medications. There were no detectable differences between HCTZ and INDAP in metabolic adverse effects, including effects on serum potassium. In conclusion, these head-to-head comparisons demonstrate that, like chlorthalidone, INDAP is more potent than HCTZ at commonly prescribed doses without evidence for greater adverse metabolic effects.
Subject(s)
Blood Pressure/drug effects , Chlorthalidone/therapeutic use , Hydrochlorothiazide/therapeutic use , Hypertension/drug therapy , Indapamide/therapeutic use , Potassium/blood , Diuretics/therapeutic use , Humans , Hypertension/blood , Hypokalemia/blood , Hypokalemia/chemically induced , Hypokalemia/prevention & control , Treatment OutcomeABSTRACT
Accounting for 15 % of deaths worldwide, hypertension is often treated with hydrochlorothiazide (HCTZ) (50 million prescriptions annually). HCTZ has a <24-h duration of action, is less potent than chlorthalidone and all major antihypertensive drug classes, and is inferior to four antihypertensive drugs for cardiovascular event (CVE) reduction. If there were alternative diuretics, why prescribe HCTZ? Chlorthalidone is often offered as an alternative to HCTZ, but has limited pharmaceutical formulations. However, there are seven evidence-based, single-tablet, alternative diuretics. For reducing CVE, the following are superior to their comparators: chlorthalidone versus four antihypertensives in multiple hypertensive populations; indapamide versus placebo in elderly Chinese (and versus enalapril for left ventricular hypertrophy), triamterene-HCTZ versus placebo in elderly Europeans, amiloride-HCTZ versus three antihypertensives, and indapamide-perindopril versus placebo in three populations. Additionally, chlorthalidone-azilsartan and spironolactone-HCTZ are potent combinations The aldosterone antagonist component of the latter combination has been shown to reduce total mortality by 30 % in heart failure. Five of these seven have multiple dose formulations. Six cost $4-$77 monthly. In conclusion, based on both scientific and practical grounds, new prescriptions for HCTZ are rarely justified.